Lucid DiagnosticsLUCD +0.48%26 Receivables Turnover is 1.89 as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Lucid Diagnostics ranks better than 90.02% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lucid Diagnostics's Revenue for the
three
months ended in Mar. 2026 was $1.26 Mil. Lucid Diagnostics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.67 Mil.
Hence, Lucid Diagnostics's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.89.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Lucid Diagnostics Receivables Turnover Related Terms
Lucid Diagnostics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs QTRX, INFU, APYX: Receivables Turnover Comparison
For the Medical Devices subindustry, Lucid Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Receivables Turnover of 1.89 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lucid Diagnostics and its competitors. According to the industry distribution chart, Lucid Diagnostics ranks #81 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 10%.
Is Lucid Diagnostics' Receivables Turnover too high?
Lucid Diagnostics' current Receivables Turnover is 1.89. The Medical Devices & Instruments industry median Receivables Turnover is 5.57. Lucid Diagnostics' value of 1.89 is 66% below this industry median. Based on the distribution chart, Lucid Diagnostics ranks #81 out of 812 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Receivables Turnover compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #81 out of 812 companies for Receivables Turnover. This places Lucid Diagnostics in the top 10% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.57. Lucid Diagnostics' value of 1.89 is 66% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.57, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current Receivables Turnover of 1.89 is 66% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Receivables Turnover is 1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.06 — trading 30.2% above its estimated fair value. The current Receivables Turnover is 1.89 and 66% below the Medical Devices & Instruments industry median of 5.57. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Receivables Turnover is 1.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.06 is trading 30.2% above its estimated GF Value™ of $0.81.
GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.
Key valuation signals for LUCD:
Receivables Turnover: 1.89
GF Value™: $0.81 vs. price of $1.06 (30.2% above fair value)
Industry Position: 66% below the Medical Devices & Instruments median (#81 of 812)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score
Get the complete analysis for LUCD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
